

**Supplementary Table S1.** Changes in HMI and CMI responses in patients treated with HD or PD and in control participants after completing COVID-19 vaccination with the extended primary series, composed of a heterologous inactivated SARS-CoV-2 prime-boost and ChAdOx1 nCoV-19 vaccine as the third dose, beginning from baseline (M0) and continuing through 3 months (M3) and 6 months (M6) after vaccination.

Variable	HD	PD	Control
N (%) or mean (SD)	(n = 29)	(n = 28)	(n = 14)
Percent change in anti-RBD IgG titer from M0 to M3 [%], mean (SD)	−59.5%*** (27.9%)	−69.1% (17.1%)	−80.2% (11%)
Percent change in anti-RBD IgG titer from M0 to M6 [%], mean (SD)	−76.7% (18.7%)	−84.1% (9.6%)	N/A
Percent change in sVNT from M0 to M3 [%], median (IQR)	−6% (−15% to −1%)	−5% (−20% to −2%)	−6% (−16% to −2%)
Percent change in sVNT from M0 to M6 [%], median (IQR)	−8% (−15% to −1%)	−13% (−30% to −5%)	N/A

Percent change in S1-specific T-cell response from M0 to M6 [%], median (IQR)	6% (-77% to 329%)	14% (-43% to 170%)	N/A
---	----------------------	-----------------------	-----

\*\*\*  $p < 0.05$  (compared with control participants)

*CMI*, cell-mediated immunity; *HD*, hemodialyzed patients; *HMI*, humoral-mediated immunity; *IgG*, immunoglobulin G; *IQR*, interquartile range; *N*, number; *N/A*, not applicable; *PD*, peritoneal dialyzed patients; *RBD*, receptor-binding domain; *SD*, standard deviation; *sVNT*, surrogate virus neutralization test.